{{Drugbox
| IUPAC_name = N-Ethyl-1,2-diphenylethylamine
| image = Ephenidine.svg

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_UK = PSA 
| legal_status = Illegal in Sweden
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 60951-19-1 
| CAS_number2 = 6272-97-5
| index_label =
| index2_label = HCl
| ATC_prefix = 
| ATC_suffix = 
| PubChem =  110821
| PubChem2 = 110820
| ChemSpiderID = 99470
| ChemSpiderID2 = 99469
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = NG69VG2948

<!--Chemical data-->
| C=16 | H=19 | N=1
| molecular_weight = 225.328 g/mol
| melting_point =
| smiles            = CCNC(CC1=CC=CC=C1)C2=CC=CC=C2
| smiles2           = CCNC(CC1=CC=CC=C1)C2=CC=CC=C2.Cl
| StdInChI          = 1S/C16H19N/c1-2-17-16(15-11-7-4-8-12-15)13-14-9-5-3-6-10-14/h3-12,16-17H,2,13H2,1H3
| StdInChI2         = 1S/C16H19N.ClH/c1-2-17-16(15-11-7-4-8-12-15)13-14-9-5-3-6-10-14;/h3-12,16-17H,2,13H2,1H3;1H
| StdInChIKey       = IGFZMQXEKIZPDR-UHFFFAOYSA-N
| StdInChIKey2      = WOSDTAOMYCNNJE-UHFFFAOYSA-N
}}

'''Ephenidine''' (also known as '''NEDPA''' and '''EPE''') is a [[Dissociative drug|dissociative]] [[anesthesia|anesthetic]] that has been sold online as a [[designer drug]].<ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1620/abstract | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs |author1=Hamilton Morris |author2=Jason Wallach | journal=Drug Testing and Analysis |date=July–August 2014 | volume=6 | issue=7–8 | pages=614–632 | doi=10.1002/dta.1620 | pmid=24678061}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0378427412014415 | title=Michaelis–Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein |author1=Markus R. Meyer |author2=Tina Orschiedt |author3=Hans H. Maurer | journal=Toxicology Letters | date=February 2013 | volume=217 | issue=2 | pages=137–142 | doi=10.1016/j.toxlet.2012.12.012 | pmid=23273999}}</ref> It is illegal in some countries as a [[structural isomer]] of the banned opioid drug [[lefetamine]], but has been sold in countries where it is not yet banned.<ref name="Wink_2014">{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1621/abstract | title=Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): Metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS |author1=Carina S. D. Wink |author2=Golo M. J. Meyer |author3=Dirk K. Wissenbach |author4=Andrea Jacobsen-Bauer |author5=Markus R. Meyer |author6=Hans H. Maurer | journal=Drug Testing and Analysis |date=October 2014  | volume=6 | issue=10 | pages=1038–1048 | doi=10.1002/dta.1621 | pmid=24591097}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0378427415300333 | title=Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs – Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps |author1=Carina S.D. Wink |author2=Golo M.J. Meyer |author3=Markus R. Meyer |author4=Hans H. Maurer | journal=Toxicology Letters |date=November 2015  | doi=10.1016/j.toxlet.2015.08.012 | pmid=26276083 | volume=238 | issue=3 | pages=39–44}}</ref>

==Pharmacology==

===Pharmacodynamics===
Ephenidine and related diarylethylamines have been studied in vitro as treatments for neurotoxic injuries, and are [[Receptor antagonist|antagonists]] of the [[NMDA receptor]] (K<sub>i</sub> = 66.4&nbsp;nM for ephenidine).<ref>{{cite web | url=https://www.surechembl.org/document/EP-0346791-B1/ | title=Patent EP 0346791 - 1,2-diarylethylamines for treatment of neurotoxic injury | via=SureChEMBL | publisher=G.D. Searle, LLC | date=6 April 1994 | author1=Nancy M. Gray | author2=Brian K. Cheng}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0968089609002624 | title=NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds |author1=Michael L. Berger |author2=Anna Schweifer |author3=Patrick Rebernik |author4=Friedrich Hammerschmidt | journal=Bioorganic & Medicinal Chemistry |date=May 2009  | volume=17 | issue=1 | pages=3456–3462 | doi=10.1016/j.bmc.2009.03.025 | pmid=19345586}}</ref><ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1689/abstract | title=Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers |author1=Jason Wallach |author2=Pierce V. Kavanagh |author3=Gavin McLaughlin |author4=Noreen Morris |author5=John D. Power |author6=Simon P. Elliott |author7=Marion S. Mercier |author8=David Lodge |author9=Hamilton Morris |author10=Nicola M. Dempster |author11=Simon D. Brandt | journal=Drug Testing and Analysis |date=May 2015  | volume=7 | issue=5 | pages=358–367 | doi=10.1002/dta.1689 | pmid=25044512}}</ref><ref>{{cite journal|first1=Andrew|last1=Thurkauf|first2=James|last2=Monn|first3=Marienna V.|last3=Mattson|first4=Arthur E.|last4=Jacobson|title=Structural and conformational aspects of the binding of aryl-alkyl amines to the phencyclidine binding site|url=http://archives.drugabuse.gov/pdf/monographs/95.pdf|journal=NIDA research monograph|date=1989|issn=1046-9516|pages=51–56|volume=95|first5=Kenner C.|last5=Rice|pmid=2561843}}</ref><ref>{{cite journal|first1=L. H.|last1=Goodson|first2=C. J. W.|last2=Wiegand|first3=Janet S.|last3=Splitter|title=Analgesics. I. N-Alkylated-1,2-diphenylethylamines Prepared by the Leuckart Reaction|url=http://pubs.acs.org/doi/abs/10.1021/ja01215a018|journal=Journal of the American Chemical Society|date=November 1946|pages=2174–2175|volume=68|issue=11|doi=10.1021/ja01215a018|pmid=21002222}}</ref> Ephenidine also possesses weaker affinity for [[Dopamine transporter|dopamine]] and [[norepinephrine transporter]]s (379&nbsp;nM and 841&nbsp;nM, respectively) as well as [[Sigma-1 receptor|σ<sub>1</sub>R]] (629&nbsp;nM) and [[Sigma-2 receptor|σ<sub>2</sub>R]] (722&nbsp;nM) binding sites.<ref>{{cite journal|first1=Heather|last1=Kang|first2=Pojeong|last2=Park|first3=Zuner A.|last3=Bortolotto|first4=Simon D.|last4=Brandt|title=Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties|url=http://www.sciencedirect.com/science/article/pii/S0028390816303392|journal=Neuropharmacology|doi=10.1016/j.neuropharm.2016.08.004|first5=Tristan|last5=Colestock|first6=Jason|last6=Wallach|first7=Graham L.|last7=Collingridge|first8=David|last8=Lodge|date=2016|volume=112|issue=Pt A|pages=144–149|pmid=27520396|pmc=5084681}}</ref>

===Pharmacokinetics===

===Metabolism===
Ephenidine's [[metabolic pathway]] consists of N-oxidation, N-dealkylation, mono- and bis-hydroxylation of the benzene ring, and hydroxylation of the phenyl ring only after N-dealkylation. The dihydroxy metabolites were conjugated by methylation of one hydroxy group, and hydroxy metabolites by glucuronidation or sulfation.<ref name="Wink_2014" /><ref>{{cite journal | url=https://link.springer.com/article/10.1007%2Fs00216-014-8414-3 | title=Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MSn, and LC-high resolution-MS/MS |author1=Carina S. D. Wink |author2=Golo M. J. Meyer |author3=Josef Zapp |author4=Hans H. Maurer | journal=Analytical and Bioanalytical Chemistry |date=February 2015  | volume=407 | issue=6 | pages=1545–1557 | doi=10.1007/s00216-014-8414-3 | pmid=25577353}}</ref>

==Chemistry==
Ephenidine reacts with [[pill testing|reagent tests]] to give a semi-unique array of colors which can be used to aid its identification.

{| class="wikitable"
|+ Final colors produced by reagent tests<ref name="RTUK ephenidine">{{cite web | url=https://www.reagent-tests.uk/blog/ephenidine-reaction-results-with-various-reagent-tests/ | title=Ephenidine reaction results with various reagent tests | publisher=Reagent Tests UK | date=17 January 2016 | accessdate=23 January 2016}}</ref>
|-
!Reagent
!Reaction color
|-
| Marquis
| Orange > Brown
|-
| Mandelin
| Green
|-
| Liebermann
| Deep red > Brown (fast)
|-
| Froehde
| Light Yellow
|}

==Society and culture==

===Legality===
Sweden's public health agency suggested that Ephenidine be classified as a hazardous substance on 1 June 2015. Due to that suggestion, Ephenidine became a scheduled substance, in Sweden, as of 18 August 2015.<ref>{{cite web | url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/juni/23-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara | title=23 nya ämnen kan klassas som narkotika eller hälsofarlig vara | publisher=Folkhälsomyndigheten | language=sv | date=1 June 2015}}</ref>

In Canada, MT-45 and its analogues were made Schedule I controlled substances.<ref>{{cite journal | url=http://www.gazette.gc.ca/rp-pr/p2/2016/2016-06-01/html/sor-dors106-eng.php | title=Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18) | author=Denis Arsenault | journal=Canada Gazette | date=1 June 2016 | volume=150 | issue=11 | publisher=Government of Canada}}</ref> Possession without legal authority can result in maximum 7 years imprisonment. Further, [[Health Canada]] amended the ''Food and Drug Regulations'' in May, 2016 to classify AH-7921 as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.

==See also==
* [[AD-1211]]
* [[Diphenidine]]
* [[Fluorolintane]]
* [[Lanicemine]]
* [[Methoxphenidine]] (MXP)
* [[MT-45]]
* [[NPDPA]]
* [[Remacemide]]
* [[UWA-001]]

==References==
{{Reflist|30em}}

{{Hallucinogens}}
{{Ionotropic glutamate receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Sigma receptor modulators}}

[[Category:Designer drugs]]
[[Category:Diarylethylamines]]
[[Category:Dissociative drugs]]
[[Category:Norepinephrine-dopamine reuptake inhibitors]]
[[Category:NMDA receptor antagonists]]
[[Category:Sigma receptor ligands]]